<DOC>
	<DOCNO>NCT02785250</DOCNO>
	<brief_summary>Immunotherapeutic survivin vaccine DPX-Survivac , low dose oral cyclophosphamide , IDO1 inhibitor epacadostat test together first time patient recurrent ovarian , fallopian tube , peritoneal cancer determine safety potential immune-modulating activity combination agent .</brief_summary>
	<brief_title>Study DPX-Survivac Vaccine Therapy Epacadostat Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Key Histologically confirm stage IIcIV epithelial ovarian , fallopian tube peritoneal cancer Platinumresistant sensitive complete firstline treatment ( debulking surgery adjuvant neoadjuvant treatment standard care treatment carboplatin paclitaxel ) Complete partial response stable disease radiological imaging recent standard care chemotherapy treatment Evidence progressive disease rise CA125 and/or radiologic progression Must measurable disease , successful pretreatment tumor biopsy , willing undergo tumor biopsy treatment Ambulatory ECOG 01 Life expectancy â‰¥ 6 month Meet protocolspecified lab requirement Key Eligible otherwise curative treatment undergoing concurrent therapy Prior receipt survivin base vaccine immune checkpoint inhibitor ( e.g . antiCTLA4 , antiPD1 , antiPDL1 , antibody drug specifically target T cell costimulation ) IDO inhibitor Concurrent second malignancy nonmelanoma skin cancer , cervical carcinoma situ , control bladder cancer Clinical ascites metastatic pleural fluid Malignant bowel obstruction History autoimmune disease require treatment within last two year ( except vitiligo diabetes ) Recent history thyroiditis Presence serious acute infection chronic infection Active central nervous system ( CNS ) leptomeningeal metastasis ( brain metastasis ) GI condition might limit absorption oral agent Other serious intercurrent chronic acute illness Ongoing treatment steroid therapy immunosuppressive Receipt monoamine oxidase inhibitor ( MAOIs ) UGT1A9 inhibitor Acute chronic skin and/or microvascular disorder Edema lymphedema low limb &gt; grade 1</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>IDO1 inhibitor</keyword>
	<keyword>ovarian</keyword>
	<keyword>fallopian tube</keyword>
	<keyword>peritoneal</keyword>
	<keyword>cancer</keyword>
	<keyword>recurrent</keyword>
	<keyword>tumor</keyword>
	<keyword>measurable</keyword>
</DOC>